By 2030, it is anticipated that the Romania Oncology Therapeutics Market will reach a value of $1023 Mn from $527 Mn in 2022, growing at a CAGR of 8.65% during 2022-30. The Oncology Therapeutics Market in Romania is dominated by a few domestic pharmaceutical companies such as Ropharma, Oncogene, and Rovis Pharma. The Oncology Therapeutics Market in Romania is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Romania Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
By 2030, it is anticipated that the Romania Oncology Therapeutics Market will reach a value of $1023 Mn from $527 Mn in 2022, growing at a CAGR of 8.65% during 2022-30.
Romania is an upper-middle-income, developed country located at the crossroads of Central and Southeastern Europe. In Romania in 2020, there were 53,881 new cancer cases in men and 45,005 new cancer cases in women. Lung cancer (16.8%) and other cancers were the most prevalent cancer kinds among men (41.5%). Breast cancer was the most common among females (22.6%), followed by other malignancies (41.7%).
According to the Federation of Associations of Cancer Patients (FABC), cancer mortality in Romania is 48% higher than in the rest of the EU. It is predicted that the number of cancer cases in the European Union would rise by 24% by 2035, making cancer the leading cause of death. Romania's government spent 6.3% of its GDP on healthcare in 2020.
Market Growth Drivers Analysis
Clinical research is rapidly developing, and despite initial delays imposed by slow study approval by authorities, Romanian institutes have a high recruitment rate in pivotal studies. In accordance with the World Health Organization's MPOWER initiatives, tough anti-tobacco policies were recently implemented. Cancer is Romania's second greatest cause of death after cardiovascular diseases and medications used to treat cancer are funded through a special National Oncology Program. Because of its low labour costs, Romania boasts a diverse and competitive industry. The EU includes Romania in its "Golden Growth" scheme in 2001. These aspects could boost Romania's Oncology Therapeutics Market.
Market restraints
Our country has nationally mandated state insurance coverage that covers cancer diagnosis, treatment, and follow-up expenditures. However, individuals with cancer continue to face a variety of administrative and social challenges due to coverage gaps. In Romania, any new drugs approved by the European Medicines Agency in Europe are likewise approved. However, no new drugs or indications (such as first-line tyrosine-kinase inhibitors or maintenance treatment) have been approved for reimbursement since 2008. These factors may deter new entrants into the Romania Oncology Therapeutics Market.
Key Players
In Romania, the administrative body responsible for endorsing and checking oncology therapeutics is the National Agency for Medicines and Medical Devices (ANMDM)., Romania has a public health care coverage scheme known as the National Health Insurance Fund (CNAS). Moreover, a few non-legislative associations (NGOs) give monetary help to disease patients who can't manage the cost of their medicines. The Romanian government has carried out different drives to further develop access to oncology therapeutics in the nation, including the "National Cancer Control Plan."
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Oncology Therapeutics Segmentation
By Application (Revenue, USD Billion):
By Drugs (Revenue, USD Billion):
By Therapy (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Romania Oncology Therapeutics market will reach a value of $1023 Mn from $527 Mn in 2022, growing at a CAGR of 8.65% during 2022-2030.
In Romania, the administrative body responsible for endorsing and checking oncology therapeutics is the National Agency for Medicines and Medical Devices (ANMDM).
The Oncology Therapeutics Market in Romania is dominated by a few domestic pharmaceutical companies such as Ropharma, Oncogene, and Rovis Pharma.